Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 517472, 7 pages
http://dx.doi.org/10.1155/2015/517472
Clinical Study

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

1Kagawa University School of Medicine, Kagawa 761-0793, Japan
2Jichi Medical University School of Medicine, Tochigi, Japan
3Tulane University Health Sciences Center, New Orleans, LA, USA
4Miyazaki University School of Medicine, Miyazaki, Japan

Received 11 November 2014; Revised 1 February 2015; Accepted 9 February 2015

Academic Editor: Bagher Larijani

Copyright © 2015 Tomoko Mizushige et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Kobori, M. Kamiyama, L. M. Harrison-Bernard, and L. G. Navar, “Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy,” Journal of Investigative Medicine, vol. 61, no. 2, pp. 256–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Nagai, L. Yao, H. Kobori et al., “Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 703–711, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Suzaki, Y. Ozawa, and H. Kobori, “Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats,” International Journal of Biological Sciences, vol. 3, no. 1, pp. 40–46, 2007. View at Google Scholar · View at Scopus
  5. K. Miyata, N. Ohashi, Y. Suzaki, A. Katsurada, and H. Kobori, “Sequential activation of the reactive oxygen species/angiotensinogen/renin- angiotensin system axis in renal injury of type 2 diabetic rats,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 8, pp. 922–927, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kamiyama, M. Urushihara, T. Morikawa et al., “Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy,” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 23045–23062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. W. J. Liu, S. H. Xie, Y. N. Liu et al., “Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 2, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. R. Rizzo, M. Barbieri, R. Marfella, and G. Paolisso, “Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition,” Diabetes Care, vol. 35, no. 10, pp. 2076–2082, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Kodera, K. Shikata, H. U. Kataoka et al., “Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes,” Diabetologia, vol. 54, no. 4, pp. 965–978, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. K. W. Joo, S. Kim, S.-Y. Ahn et al., “Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney,” BMC Nephrology, vol. 14, no. 1, article 98, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. K. D. Burns and S. Hiremath, “Urinary angiotensinogen as a biomarker of chronic kidney disease: ready for prime time?” Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3010–3013, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Nishiyama, Y. Konishi, N. Ohashi et al., “Urinary angiotensinogen reflects the activity of intrarenal reninangiotensin system in patients with IgA nephropathy,” Nephrology Dialysis Transplantation, vol. 26, no. 1, pp. 170–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. T. Mills, H. Kobori, L. L. Hamm et al., “Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3176–3181, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Kobori and M. Urushihara, “Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease,” Pflugers Archiv European Journal of Physiology, vol. 465, no. 1, pp. 3–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Ogawa, H. Kobori, N. Ohashi et al., “Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy,” Biomarker Insights, vol. 2009, no. 4, pp. 97–102, 2009. View at Google Scholar · View at Scopus
  16. T. Saito, M. Urushihara, Y. Kotani, S. Kagami, and H. Kobori, “Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes,” The American Journal of the Medical Sciences, vol. 338, no. 6, pp. 478–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Sawaguchi, S.-I. Araki, H. Kobori et al., “Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus,” Journal of Diabetes Investigation, vol. 3, no. 3, pp. 318–324, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Matsuo, E. Imai, M. Horio et al., “Revised equations for estimated GFR from serum creatinine in Japan,” The American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982–992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Katsurada, Y. Hagiwara, K. Miyashita et al., “Novel sandwich ELISA for human angiotensinogen,” American Journal of Physiology: Renal Physiology, vol. 293, no. 3, pp. F956–F960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Kobori, L. M. Harrison-Bernard, and L. G. Navar, “Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension,” Journal of the American Society of Nephrology, vol. 12, no. 3, pp. 431–439, 2001. View at Google Scholar · View at Scopus
  21. N. Yanagawa, A. W. Capparelli, O. D. Jo, A. Friedal, J. D. Barrett, and P. Eggena, “Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture,” Kidney International, vol. 39, no. 5, pp. 938–941, 1991. View at Publisher · View at Google Scholar · View at Scopus
  22. P. P. Leyssac, “Changes in single nephron renin release are mediated by tubular fluid flow rate,” Kidney International, vol. 30, no. 3, pp. 332–339, 1986. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Sibony, J.-M. Gasc, F. Soubrier, F. Alhenc-Gelas, and P. Corvol, “Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme,” Hypertension, vol. 21, no. 6, pp. 827–835, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Matsusaka, F. Niimura, A. Shimizu et al., “Liver angiotensinogen is the primary source of renal angiotensin II,” Journal of the American Society of Nephrology, vol. 23, no. 7, pp. 1181–1189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Matsusaka, F. Niimura, I. Pastan, A. Shintani, A. Nishiyama, and I. Ichikawa, “Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation,” Kidney International, vol. 85, no. 5, pp. 1068–1077, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Nakano, H. Kobori, J. L. Burford et al., “Multiphoton imaging of the glomerular permeability of angiotensinogen,” Journal of the American Society of Nephrology, vol. 23, no. 11, pp. 1847–1856, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Kagami, W. A. Border, D. E. Miller, and N. A. Noble, “Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells,” Journal of Clinical Investigation, vol. 93, no. 6, pp. 2431–2437, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Yamamoto, T. Nakamura, N. A. Noble, E. Ruoslahti, and W. A. Border, “Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 5, pp. 1814–1818, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Ha and H. Endou, “Lipid peroxidation in isolated rat nephron segments,” The American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 263, no. 2, pp. F201–F207, 1992. View at Google Scholar · View at Scopus
  30. H. Ha and H. B. Lee, “Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose,” Kidney International, Supplement, vol. 58, supplement 77, pp. S19–S25, 2000. View at Google Scholar · View at Scopus
  31. S. Ogawa, M. Matsushima, T. Mori et al., “Identification of the stages of diabetic nephropathy at which angiotensin II receptor blockers most effectively suppress albuminuria,” American Journal of Hypertension, vol. 26, no. 9, pp. 1064–1069, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. B. M. Brenner, M. E. Cooper, D. De Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Soltysiak, B. Skowronska, P. Fichna et al., “Urinary angiotensinogen and urinary sodium are associated with blood pressure in normoalbuminuric children with diabetes,” Pediatric Nephrology, vol. 29, no. 12, pp. 2373–2378, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Kamiyama, A. Zsombok, and H. Kobori, “Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes,” Journal of Pharmacological Sciences, vol. 119, no. 4, pp. 314–323, 2012. View at Publisher · View at Google Scholar · View at Scopus